“If BioNTech really wants to change the course of this pandemic, it should immediately share the technology and know-how for this publicly-funded innovation with the WHO’s technology pool and mRNA hub in South Africa, so that more developing country manufacturers can produce these game-changing vaccines.”

“Offering to only start building a facility in Africa in the middle of next year that will then at some point produce just 50 million doses – enough for just 2 per cent of the continent’s population – is a pittance when just one of their factories in Germany produces more than that each month. While this is a positive development, it’s far too little, far too late from a company that has made a killing from the pandemic. “After huge public pressure, BioNTech has finally committed to manufacturing vaccines in the global south. Reacting to BioNTech’s announcement, Anna Marriott, policy lead for the People’s Vaccine Alliance, said: While the alliance calls more global south manufacturing a “positive development”, it says BioNTech’s offer of 50 million doses from the middle of next year is “pittance” compared to the amount produced in the company’s facilities in Germany. The alliance, a coalition of more than 75 organisations including Oxfam, UNAIDS, Global Justice Now, and Amnesty International, has called on BioNTech and Moderna to share the technology and know-how for its vaccine with the WHO’s Covid-19 technology access pool (C-TAP) and mRNA hub in South Africa. The People’s Vaccine Alliance has also said that Moderna’s new commitment to produce 110 million doses for the African Union as “barely worth the paper it is written on” after the company failed to deliver promised vaccines to COVAX, calling on the US government to step in and mandate the company to commit to technology transfer. Vaccine equity campaigners have called news that Covid-19 vaccine manufacturer BioNTech will start building a vaccine production facility in Rwanda next year “far too little, far too late”.

Moderna vaccine production facility